Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.